22-1keynote 22JPM

NEUROPHTH THERAPEUTICS Inc. to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 27th, 2021 (Shanghai) — We are glad to announce that Alvin Luk, the CEO of NEUROPHTH THERAPEUTICS Inc.(纽福斯生物), has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

Speech Topic: Advances in Gene Therapy and Future Prospect


About the speaker

Dr. Alvin Luk is the Chief Executive Officer at Neurophth, bringing over 28 years of leadership experience in global drug development, strategic portfolio management and clinical development. Dr. Luk has held various management positions in clinical research and medical affairs at different companies, including Shanghai Henlius Biotech, Spark Therapeutics, Biogen-Hemophilia (acquired by Sanofi), Bayer-Schering Pharma, Avigen (acquired by Sanofi) and Tularik (acquired by Amgen) of progressive responsibilities since the late 1990s. Dr. Luk oversaw the clinical research and development, global medical affairs strategy and execution, resulting in winning the regulatory approval of 18 products in neurology, ophthalmology, hematology, gene / cell therapy and cancer therapy as of today. Spark Therapeutics’ LUXTURNA® was approved as the first gene therapy product by the FDA in 2017. Dr. Luk was the Head of Clinical Research and Operation, participated in the development of LUXTURNA®, and led the clinical development and strategy of multiple AAV gene therapy candidates. Dr. Luk also served as a member at the industrial board of the U.S. FDA Rare Diseases Clinical Design Committee, focusing on optimizing the clinical trial design to shorten drug development between 2006-2009.

Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cells, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from the Harvard Business School. He is ACRP-certified in clinical research and also received his Ph.D. in Neuroscience from the University of California, San Francisco.


陆英明(Alvin Luk)博士是纽福斯生物的CEO,在全球药物开发、战略、产品组合管理和临床开发方面拥有超过28年的领导经验。陆博士自90年代末便开始在不同公司担任多个行政管理职位,包括复宏汉霖、Spark Therapeutics、百健-血友病公司(被赛诺菲收购)、拜耳医药、Avigen公司(被赛诺菲收购)和Tularik公司(被安进公司收购)。陆博士负责领导临床研发、全球医疗战略和执行,先后领导或参与18种产品获得监管批准上市,产品覆盖神经科、眼科、血液科、基因/细胞治疗和癌症治疗等疾病领域。Spark Therapeutics公司的LUXTURNA®于2017年被美国FDA批准为首个基因治疗产品,陆博士届时担任临床研究和运营负责人,参与了LUXTRUNA®的开发并领导了多个AAV基因治疗临床开发和战略制定。2006至2009年期间,陆博士还担任美国食品药品监督管理局(U.S. FDA)罕见病临床设计委员会工业委员会的成员之一,专注于优化临床试验设计以缩短药物开发时间。



Neurophth is China’s first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.


ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

If you are interested in listening to the live event, please register at https://biotochina.org/register/

Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang